A nurse is caring for a client who is taking sucralfate. Which of the following outcomes indicates a therapeutic effect of the medication?

Choice A reason: Sucralfate is a mucosal protectant that forms a gel-like barrier over gastric ulcers, shielding them from acid and pepsin. It does not have antimicrobial properties to prevent opportunistic infections, which are typically managed by antibiotics or antifungals targeting pathogens like Candida or Pneumocystis in immunocompromised patients. Choice B reason: Sucralfate acts locally in the gastrointestinal tract, coating ulcerated mucosa to promote healing. It has no systemic effects on ocular structures or neural pathways involved in vision. Impaired vision may result from conditions like cataracts or glaucoma, which require specific ophthalmic treatments, not mucosal protectants. Choice C reason: Sucralfate’s therapeutic effect involves forming a protective barrier over gastric or duodenal ulcers, reducing irritation from stomach acid and pepsin, thus alleviating gastrointestinal pain. This local action promotes ulcer healing and symptom relief, making pain reduction a direct indicator of its efficacy in peptic ulcer disease management. Choice D reason: Sucralfate does not affect glucose metabolism or insulin secretion. Blood glucose reduction is managed by antidiabetic agents like metformin or insulin, which target pancreatic beta cells or glucose uptake. Sucralfate’s action is confined to the gastrointestinal tract, with no impact on endocrine pathways regulating blood sugar.